États-Unis · Plateformes & données · MarketBeat

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option

Publié par MarketBeat · États-Unis il y a 3 h

Prelude Therapeutics (NASDAQ:PRLD) outlined progress across three priority programs at a Chardan Capital investor session, emphasizing its recently initiated JAK2 program, an…

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option

À lire aussi

Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy?

Gjensidige Forsikring reports strong Q3 profit beat

My partner of 17 years left me his $1 million home. His children are crying foul. Am I obliged to split it with them?

Volvo Cars Q3 2026: taking decisive action to navigate a very tough environment

Fundstrat's Tom Lee Is Bullish On Broad Cyclical Trade: ‘People Are Worried About The Credit Side, But I Think They’re Bottoming’

Norsk Hydro: Solid results and strong performance

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option

Partager

À lire aussi

Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy?

Gjensidige Forsikring reports strong Q3 profit beat

My partner of 17 years left me his $1 million home. His children are crying foul. Am I obliged to split it with them?

Volvo Cars Q3 2026: taking decisive action to navigate a very tough environment

Fundstrat's Tom Lee Is Bullish On Broad Cyclical Trade: ‘People Are Worried About The Credit Side, But I Think They’re Bottoming’

Norsk Hydro: Solid results and strong performance